Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

C3BS Raises €19 Million Through a Private Placement

Published: Tuesday, July 09, 2013
Last Updated: Tuesday, July 09, 2013
Bookmark and Share
New funds will be used to finance the on-going clinical development of C-Cure®.

Cardio3 BioSciences (C3BS) has announced that it has increased its equity by €19 million through a private placement with existing investors.

The new funds will be used to finance the on-going clinical development of the Company’s lead product, C-Cure®, currently tested in Europe in a Phase III trial (CHART-1 - Congestive Heart failure Cardiopoietic Regenerative Therapy) and the preclinical development of other product candidates.

CHART-1 is the world’s first phase III trial using pre-programmed cardiac progenitor cells and targeting heart failure.

Of the €19 million raised, €7 million is in new equity committed by existing investors with €12 million resulting from the conversion of existing convertible loans.

The formal capital increase was approved at a shareholder meeting and is expected to complete by the end of May 2013.

C3BS’ C-Cure is a unique therapy that allows the reprogramming of bone marrow cells into ‘cardiopoïetic’ cells with the aim of growing new heart tissue thereby repairing damaged heart muscle.

The cardiopoietic cells are injected into the patient’s heart through a minimally invasive procedure using a proprietary catheter called C-Cath®ez.

C-Cure is the outcome of research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre Aalst (Aalst, Belgium).

Christian Homsy, CEO of Cardio3 BioSciences commenting on today’s announcement said, “Our ability to raise this significant amount of funding demonstrates the commitment of our investors and their confidence in the considerable value that we can generate from C-Cure. The new funding will allow us to proceed with our European Phase III trial in patients with Congestive Heart failure. We are confident that this study will confirm that C-Cure has the potential to significantly improve the disease course of those very sick patients, and could lead to a paradigm shift in the treatment of heart failure.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Results from C3BS C-CURE® Trial Published in the Journal of the ACC
Trial demonstrates statistically significant improvements in heart function and exercise tolerance with cardiopoietic stem cell therapy.
Monday, April 15, 2013
C3BS Receives Authorization from Belgian FAMHP
Company to begin world’s first phase III clinical trial in regenerative medicine for heart failure.
Friday, November 23, 2012
Cardio3 BioSciences Announces Significant Progress in its Programme for the Treatment of Acute Myocardial Infarction
The Belgian biotechnology company, Cardio3 BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, have announced positive pre-clinical results from its in-house product candidate C3BS-GQR-1, a “cardiopoietic” cocktail designed to treat patients suffering from acute myocardial infarction in order to protect cardiac tissue from damage and direct heart stem cells to mature and restore pump function.
Friday, December 24, 2010
Scientific News
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Bio-Mimicry Method For Preparing & Labeling Stem Cells Developed
Method allows researchers to prepare mesenchymal stem cells and monitor them using MRI.
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
New Bio-Glass Could Make it Possible to Re-Grow or Replace Cartilage
Researchers at Imperial College London have developed a material that can mimic cartilage and potentially encourage it to re-grow.
Stem Cell Advance Could Be Key Step Toward Treating Deadly Blood Diseases
UCLA scientists get closer to creating blood stem cells in the lab.
Harnessing Engineered Slippery Surfaces For Tissue Repair
A new method could facilitate the transfer of intact regenerating cell sheets from the culture dish to damaged tissues in patients.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
Stem Cell Gene Therapy For Fatal Childhood Disease Ready For Human Trial
A pioneering approach for Sanfilippo disease, a genetic condition for which there is no effective treatment, will now be trialled in humans.
Insulin-secreting Cells from Stem Cells
Stem cells from diabetic patients coaxed to become insulin-secreting cells. If damaged cells are replaceable, type 1 diabetics wouldn't need insulin shots.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!